Pharmacist assisted medication program enhancing the regulation of diabetes (PAMPERED) study

Journal of the American Pharmacists Association

Volumn 52, Issue 5, 2012, Pages 613-621

  Jacobs, Michelle ^a,b   Sherry, Pamela S ^a   Taylor, Leigh M ^a   Amato, Mary ^a,c   Tataronis, Gary R ^c   Cushing, Gary ^a,d,e  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Ambulatory care; Diabetes; Pharmacists

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; SULFONYLUREA; LIPID;

ADULT; AMBULATORY CARE; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EXERCISE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PHARMACIST; PHYSICIAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; SCREENING; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; DIET; GLUCOSE BLOOD LEVEL; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PROFESSIONAL STANDARD;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PATIENT COMPLIANCE; PHARMACISTS; PROFESSIONAL ROLE; PROSPECTIVE STUDIES;

EID: 84874418515     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2012.10183     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. Accessed at www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf, February 13, 2011.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
3. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-53.
5. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
6. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.
7. Duckworth W, Abraira C, Moritz T, et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
8. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(suppl. 1):S11-61.
9. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144:465-74.
10. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641-7.
11. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc. 2000;40:157-65.
12. Rupp MT, McCallian DJ, Sheth KK. Developing and marketing a community pharmacy-based asthma management program. J Am Pharm Assoc. 1997;NS37:694-9.
13. Hitchcock AM, Lousberg TR, Merenich J. The impact of clinical pharmacy management on cardiovascular risk reduction in patients with established heart disease in a group model health maintenance organization [abstract 135]. Phamacotherapy. 2000;20:360-1.
14. Gattis WA, Hasselblad V, Whellan DJ, et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Arch Intern Med. 1999;159:1939-45.
15. Gong C, Hasson NK, Lum BL. Impact of a diabetes disease management clinic on the total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Manag Care Pharm. 1999;5:511-5.
16. Irons BK, Lenz RJ, Anderson SL, et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002;22:1294-330.
17. Coast-Senior EA, Kroner BA, Kelley CL, et al. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636-41.
18. Odegard PS, Goo A, Hummel J, et al. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39:433-40.
19. Nowak SN, Singh R, Clarke A, et al. Metabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic. Diabetes Care. 2002;25:1479.
20. Clifford RM, Davis WA, Batty KT, et al. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2005;28:771-6.
21. Kelly C, Rodgers PT. Implementation and evaluation of a pharmacist-managed diabetes service. J Manag Care Pharm. 2000;6:488-93.
22. Cranor CW, Christensen DB. The Asheville Project: short term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:149-59.
23. Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30:238-43.
24. Nau DP, Ponte CD. Effects of a community pharmacist-based diabetes patient-managed program on intermediate clinical outcome measures. J Manag Care Pharm. 2001;8:48-53.
25. Letassy NA, Armor BL, Britton M, Farmer K. Pharmacist-managed diabetes service in a family medicine practice improves patient outcomes. Diabetes Trends. 2003;suppl:21-32.
26. Rothman R, Malone R, Bryant B. Pharmacist-led, primary care-based disease management improves hemoglobin A1c in high-risk patients with diabetes. Am J Med Qual. 2003;18:51-8.
27. Ragucci KR, Fermo JD, Wessell AM, et al. Effectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy. 2005;25:1809-16.
28. McCord AD. Clinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. Pharmacotherapy. 2006;26:248-53.
29. Shane-McWhorter L, Oderda GM. Providing diabetes education and care to underserved patients in a collaborative practice at a Utah community health center. Pharmacotherapy. 2005;25:96-109.
30. Davidson MB, Karlan V, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. Am J Med Qual. 2000;15:137-42.
31. Hogue VW, Babamoto KS, Jackson TB, et al. Pooled results of community pharmacy-based diabetes education programs in underserved communities. Diabetes Spectrum. 2003;16:129-33.
32. Leal S, Herrier RN, Glover JJ, et al. Improving quality of care in diabetes through a comprehensive pharmacist-based disease management program. Diabetes Care. 2004;27:2983-4.
33. Cioffi ST, Caron MF, Kalus JS, et al. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004;38:771-5.
34. Morello CM, Zadvorny EB, Cording MA, et al. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm. 2006;63:1325-31.
35. Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005;39:1828-32.
36. Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care. 2010;16:250-5.
37. Choe HM, Mitrovich S, Dubay D, et al. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11:253-60.
38. Johnson CL, Nicholas A, Divine H, et al. Outcomes from DiabetesCARE: a pharmacist-provided diabetes management service. J Am Pharm Assoc. 2008;48:722-30.
39. Iyer R, Coderre P, McKelvey T, et al. An employer-based, pharmacist intervention model for patients with type 2 diabetes. Am J Health Syst Pharm. 2010;67:312-5.
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
41. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28:421-36.
42. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med. 2005;118:276-84.
43. Scott DM, Boyd ST, Stephan M, et al. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63:2116-22.
44. Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA. 2006;296:427-40.
45. Isetts BJ, Brown LM, Schondelmayer SW, et al. Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals. Arch Intern Med. 2003;163:1813-20.
46. Hammond RW, Schwartz AH, Campbell MJ, et al. Collaborative drug therapy management by pharmacists. Pharmacotherapy. 2003;23:1210-25.
47. National Committee for Quality Assurance. The state of health care quality: 2004. Accessed at www.ncqa.org/Portals/0/Publications/ Resource%20Library/SOHC/SOHC-2004.pdf, May 1, 2009.
48. National Committee for Quality Assurance. The state of health care quality: 2010. Accessed at www.ncqa.org/Portals/0/State%20of%20Health%20Care/ 2010/SOHC%202010%20-%20Full2.pdf, February 15, 2011.